Page last updated: 2024-11-02

oxybutynin and Day Blindness

oxybutynin has been researched along with Day Blindness in 2 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Research Excerpts

ExcerptRelevanceReference
"All medical records, including the Overactive Bladder Symptom score (OABSS), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score (IPSS) questionnaires, and uroflowmetry parameters were reviewed at each visit."1.48Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year. ( Hsiao, SM; Kuo, HC; Lin, HH, 2018)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hsiao, SM1
Lin, HH1
Kuo, HC1
Sand, PK1

Reviews

1 review available for oxybutynin and Day Blindness

ArticleYear
Elevating our therapeutic expectations in overactive bladder.
    Journal of the American Academy of Nurse Practitioners, 2004, Volume: 16, Issue:10 Suppl

    Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Constipation; Cresols; Delayed-Action Preparations; H

2004

Other Studies

1 other study available for oxybutynin and Day Blindness

ArticleYear
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
    Lower urinary tract symptoms, 2018, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Midd

2018